Orit Itzhaki
Overview
Explore the profile of Orit Itzhaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lidar M, Rimar D, David P, Jacoby E, Shapira-Frommer R, Itzhaki O, et al.
Ann Rheum Dis
. 2025 Feb;
84(2):370-372.
PMID: 39919909
No abstract available.
2.
Sdayoor I, Shouval R, Fried S, Marcus R, Danylesko I, Yerushalmi R, et al.
Blood Adv
. 2025 Jan;
PMID: 39774788
Pulmonary function tests (PFT) are recommended for hematopoietic cell transplantation (HCT) evaluation. However, their prognostic value in chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We assessed the predictive significance...
3.
Danylesko I, Shem-Tov N, Yerushalmi R, Jacoby E, Toren A, Shouval R, et al.
Curr Res Transl Med
. 2024 Sep;
72(4):103471.
PMID: 39305562
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the...
4.
Benjamini O, Fried S, Shouval R, Flynn J, Beyar-Katz O, Leslie L, et al.
Haematologica
. 2024 Jun;
109(11):3566-3577.
PMID: 38899351
The activity of anti-CD19 chimerci antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B-cell lymphoma (LBCL) is largely unknown. In a...
5.
Gross G, Alkadieri S, Meir A, Itzhaki O, Aharoni-Tevet Y, Ben Yosef S, et al.
Leukemia
. 2024 May;
38(7):1534-1540.
PMID: 38714877
CD19 CAR-T cells have led to durable remissions in patients with refractory B-cell malignancies; nevertheless, most patients eventually relapse in the long term. Many interventions aimed at improving current products...
6.
Weinstein-Marom H, Blokon-Kogan D, Levi-Mann M, Katzman C, Shalev S, Zaitsev M, et al.
Methods Mol Biol
. 2023 Dec;
2748:167-186.
PMID: 38070115
Genetic modification of tumor-infiltrating lymphocytes (TILs) or circulating T cells has become an important avenue in cancer therapy. Here we describe a comprehensive method for establishing and expanding TIL cultures...
7.
Gross G, Alkadieri S, Meir A, Itzhaki O, Aharony-Tevet Y, Ben Yosef S, et al.
bioRxiv
. 2023 Oct;
PMID: 37808778
CD19 CAR-T cells have led to durable remissions in patients with refractory B-cell malignancies; nevertheless, most patients eventually relapse in the long term. Many interventions aimed at improving current products...
8.
Fried S, Shkury E, Itzhaki O, Sdayoor I, Yerushalmi R, Shem-Tov N, et al.
Leuk Lymphoma
. 2023 Aug;
64(12):1956-1963.
PMID: 37565578
Patients with relapsed/refractory follicular lymphoma (R/R-FL) often require multiple treatment lines. We performed a phase 1b/2 single-center clinical trial of autologous point-of-care anti-CD19 chimeric antigen receptor (CAR) T-cells in R/R-FL...
9.
Markovits E, Harush O, Baruch E, Shulman E, Debby A, Itzhaki O, et al.
Cancer Immunol Res
. 2023 Apr;
11(7):909-924.
PMID: 37074069
Immunotherapy has revolutionized the treatment of advanced melanoma. Because the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of preimmunotherapy tumor biopsies from patients with melanoma...
10.
Brezinger-Dayan K, Itzhaki O, Melnichenko J, Kubi A, Zeltzer L, Jacoby E, et al.
Front Oncol
. 2022 Oct;
12:1024362.
PMID: 36276077
Adoptive cell therapy with chimeric antigen receptor (CAR) T cells has become an efficient treatment option for patients with hematological malignancies. FDA approved CAR T products are manufactured in centralized...